Altimmune Competitors

Altimmune (NASDAQ:ALT) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Valuation & Earnings

This table compares Altimmune and Zentalis Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Zentalis Pharmaceuticals has lower revenue, but higher earnings than Altimmune.

Analyst Ratings

This is a breakdown of recent recommendations for Altimmune and Zentalis Pharmaceuticals, as provided by MarketBeat.com.

Altimmune presently has a consensus price target of $31.75, suggesting a potential upside of 150.59%. Zentalis Pharmaceuticals has a consensus price target of $56.4286, suggesting a potential upside of 23.58%. Given Altimmune's higher probable upside, equities research analysts clearly believe Altimmune is more favorable than Zentalis Pharmaceuticals.

Insider & Institutional Ownership

66.2% of Altimmune shares are owned by institutional investors. Comparatively, 67.1% of Zentalis Pharmaceuticals shares are owned by institutional investors. 2.7% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Altimmune and Zentalis Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Zentalis Pharmaceuticals beats Altimmune on 5 of the 8 factors compared between the two stocks.

Altimmune (NASDAQ:ALT) and NGM Biopharmaceuticals (NASDAQ:NGM) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Risk & Volatility

Altimmune has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, NGM Biopharmaceuticals has a beta of 1.97, suggesting that its stock price is 97% more volatile than the S&P 500.

Valuation & Earnings

This table compares Altimmune and NGM Biopharmaceuticals' revenue, earnings per share (EPS) and valuation.

Altimmune has higher earnings, but lower revenue than NGM Biopharmaceuticals. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Altimmune and NGM Biopharmaceuticals, as provided by MarketBeat.com.

Altimmune presently has a consensus price target of $31.75, suggesting a potential upside of 150.59%. NGM Biopharmaceuticals has a consensus price target of $39.1111, suggesting a potential upside of 60.09%. Given Altimmune's higher probable upside, equities research analysts clearly believe Altimmune is more favorable than NGM Biopharmaceuticals.

Insider & Institutional Ownership

66.2% of Altimmune shares are owned by institutional investors. Comparatively, 49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. 2.7% of Altimmune shares are owned by insiders. Comparatively, 50.4% of NGM Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Altimmune and NGM Biopharmaceuticals' net margins, return on equity and return on assets.

Summary

NGM Biopharmaceuticals beats Altimmune on 9 of the 15 factors compared between the two stocks.

Altimmune (NASDAQ:ALT) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Risk & Volatility

Altimmune has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Profitability

This table compares Altimmune and Morphic's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Altimmune and Morphic's revenue, earnings per share (EPS) and valuation.

Altimmune has higher earnings, but lower revenue than Morphic. Morphic is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Altimmune and Morphic, as provided by MarketBeat.com.

Altimmune presently has a consensus price target of $31.75, suggesting a potential upside of 150.59%. Morphic has a consensus price target of $63.3333, suggesting a potential upside of 9.84%. Given Altimmune's higher probable upside, equities research analysts clearly believe Altimmune is more favorable than Morphic.

Insider & Institutional Ownership

66.2% of Altimmune shares are owned by institutional investors. Comparatively, 61.5% of Morphic shares are owned by institutional investors. 2.7% of Altimmune shares are owned by insiders. Comparatively, 39.5% of Morphic shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Altimmune beats Morphic on 7 of the 13 factors compared between the two stocks.

Altimmune (NASDAQ:ALT) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Volatility & Risk

Altimmune has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.

Profitability

This table compares Altimmune and Madrigal Pharmaceuticals' net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Altimmune and Madrigal Pharmaceuticals' revenue, earnings per share and valuation.

Altimmune has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Altimmune and Madrigal Pharmaceuticals, as provided by MarketBeat.

Altimmune presently has a consensus price target of $31.75, suggesting a potential upside of 150.59%. Madrigal Pharmaceuticals has a consensus price target of $167.60, suggesting a potential upside of 45.02%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than Madrigal Pharmaceuticals.

Institutional & Insider Ownership

66.2% of Altimmune shares are owned by institutional investors. Comparatively, 74.2% of Madrigal Pharmaceuticals shares are owned by institutional investors. 2.7% of Altimmune shares are owned by company insiders. Comparatively, 41.9% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Altimmune beats Madrigal Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Altimmune (NASDAQ:ALT) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Volatility & Risk

Altimmune has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500.

Profitability

This table compares Altimmune and Kura Oncology's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Altimmune and Kura Oncology's revenue, earnings per share and valuation.

Altimmune has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings for Altimmune and Kura Oncology, as provided by MarketBeat.

Altimmune presently has a consensus price target of $31.75, suggesting a potential upside of 150.59%. Kura Oncology has a consensus price target of $39.5455, suggesting a potential upside of 43.70%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than Kura Oncology.

Institutional & Insider Ownership

66.2% of Altimmune shares are owned by institutional investors. Comparatively, 94.7% of Kura Oncology shares are owned by institutional investors. 2.7% of Altimmune shares are owned by company insiders. Comparatively, 11.0% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Kura Oncology beats Altimmune on 7 of the 13 factors compared between the two stocks.

Altimmune (NASDAQ:ALT) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.

Analyst Recommendations

This is a breakdown of recent ratings for Altimmune and FibroGen, as provided by MarketBeat.

Altimmune presently has a consensus price target of $31.75, suggesting a potential upside of 150.59%. FibroGen has a consensus price target of $45.8333, suggesting a potential upside of 132.30%. Given Altimmune's stronger consensus rating and higher probable upside, analysts plainly believe Altimmune is more favorable than FibroGen.

Profitability

This table compares Altimmune and FibroGen's net margins, return on equity and return on assets.

Institutional & Insider Ownership

66.2% of Altimmune shares are owned by institutional investors. Comparatively, 75.1% of FibroGen shares are owned by institutional investors. 2.7% of Altimmune shares are owned by company insiders. Comparatively, 3.4% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Altimmune and FibroGen's revenue, earnings per share and valuation.

Altimmune has higher earnings, but lower revenue than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Altimmune has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.